Asarina Pharma Past Earnings Performance
Past criteria checks 0/6
Asarina Pharma has been growing earnings at an average annual rate of 30%, while the Pharmaceuticals industry saw earnings growing at 10.5% annually.
Key information
30.0%
Earnings growth rate
37.3%
EPS growth rate
| Pharmaceuticals Industry Growth | 30.5% |
| Revenue growth rate | n/a |
| Return on equity | -826.2% |
| Net Margin | n/a |
| Next Earnings Update | 23 May 2024 |
Recent past performance updates
Revenue & Expenses BreakdownBeta
How Asarina Pharma makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 0 | -13 | 8 | 6 |
| 30 Sep 23 | 0 | -14 | 8 | 7 |
| 30 Jun 23 | 0 | -15 | 7 | 8 |
| 31 Mar 23 | 0 | -14 | 7 | 8 |
| 31 Dec 22 | 0 | -13 | 7 | 7 |
| 30 Sep 22 | 0 | -12 | 5 | 13 |
| 30 Jun 22 | 0 | -17 | 6 | 18 |
| 31 Mar 22 | 0 | -29 | 7 | 29 |
| 31 Dec 21 | 0 | -32 | 8 | 30 |
| 30 Sep 21 | 0 | -49 | 13 | 43 |
| 30 Jun 21 | 0 | -59 | 14 | 51 |
| 31 Mar 21 | 0 | -63 | 15 | 52 |
| 31 Dec 20 | 0 | -75 | 18 | 64 |
| 30 Sep 20 | 0 | -72 | 18 | 59 |
| 30 Jun 20 | 0 | -75 | 19 | 63 |
| 31 Mar 20 | 0 | -80 | 19 | 73 |
| 31 Dec 19 | 0 | -71 | 18 | 63 |
| 30 Sep 19 | 0 | -69 | 17 | 65 |
| 30 Jun 19 | 0 | -65 | 16 | 58 |
| 31 Mar 19 | 0 | -48 | 15 | 42 |
| 31 Dec 18 | 0 | -44 | 13 | 39 |
| 30 Sep 18 | 0 | -33 | 11 | 29 |
| 30 Jun 18 | 0 | -21 | 9 | 20 |
| 31 Mar 18 | 0 | -23 | 7 | 19 |
Quality Earnings: ASAP is currently unprofitable.
Growing Profit Margin: ASAP is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ASAP is unprofitable, but has reduced losses over the past 5 years at a rate of 30% per year.
Accelerating Growth: Unable to compare ASAP's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ASAP is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (2.7%).
Return on Equity
High ROE: ASAP has a negative Return on Equity (-826.17%), as it is currently unprofitable.